PDCD1 and cancer: Immune checkpoint antagonists targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have completely changed cancer treatment, induced lasting objective reactions, and sometimes translated into overall survival (OS) benefits of multiple cancer types including breast cancer [6] (Figure 1).